UNC Lineberger News

Over 150 attend UNC Lineberger's annual scientific retreat

Over 150 attend UNC Lineberger's annual scientific retreat

More than 150 faculty, students, and fellows gathered in the Alumni Center to hear talks on HPV and Cancer given by UNC Lineberger scientists from basic, translational science, clinical, population science, and global perspectives.

Over 150 attend UNC Lineberger's annual scientific retreat - Read More…

Science, surgery, and start-ups - in depth with Dr. Nancy DeMore

Science, surgery, and start-ups - in depth with Dr. Nancy DeMore

UNC surgeon-scientist Dr. Nancy DeMore says, “As a physician, I’m acutely aware of how much more we need to learn about breast cancer and how urgently we need better therapies. It really gives me hope to be in the lab and to know that I’m working towards something that may make things better for patients.”

Science, surgery, and start-ups - in depth with Dr. Nancy DeMore - Read More…

UNC Oncology Chaplain Named North Carolina Chaplain of the Year

UNC Oncology Chaplain Named North Carolina Chaplain of the Year

Chapel Hill - Patricia Cadle, MRE, BCC, Oncology Chaplain at UNC Health Care’s Department of Pastoral Care, was honored as the 2012 Chaplain of the Year by the North Carolina Chaplains’ Association. This award is presented annually at the Association’s spring conference in recognition of “distinguished ministry in pastoral care” to a chaplain “who serves patients, community and colleagues with grace and innovation.”

UNC Oncology Chaplain Named North Carolina Chaplain of the Year - Read More…

BCBSNC Names Dr. Lisa Carey to Board of Trustees

BCBSNC Names Dr. Lisa Carey to Board of Trustees

CHAPEL HILL, N.C. – Blue Cross and Blue Shield of North Carolina (BCBSNC) has announced Dr. Lisa Carey, Medical Director of the University of North Carolina at Chapel Hill (UNC) Breast Center and Associate Director of UNC Lineberger Comprehensive Cancer Center, as the newest member of its board of trustees.

BCBSNC Names Dr. Lisa Carey to Board of Trustees - Read More…

Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers

Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers

Chapel Hill, NC – Multiple research projects – including a 2006 study conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.

Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers - Read More…

Quest to understand Hepatitis C link with liver cancer receives $2.35 million boost

Quest to understand Hepatitis C link with liver cancer receives $2.35 million boost

Chapel Hill, NC – Does hepatitis C cause liver cancer due to inflammation associated with the disease, or does the virus interact with host cells in a different way to promote the development of cancer?

Quest to understand Hepatitis C link with liver cancer receives $2.35 million boost - Read More…

Bae-Jump to serve on NCI's Gynecologic Cancer Steering Committee

Bae-Jump to serve on NCI's Gynecologic Cancer Steering Committee

Victoria Bae-Jump, MD, PhD will serve a two-year term as a junior investigator on the Gynecologic Cancer Steering Committee of the National Cancer Institute, a member institute of the National Institutes of Health.

Bae-Jump to serve on NCI's Gynecologic Cancer Steering Committee - Read More…

UNC study highlights diagnosis of lung cancer subtypes

UNC study highlights diagnosis of lung cancer subtypes

In the processes of treating most cancers, one of the key pieces of information is the appearance of the tumor under the microscope using a technique called light microscopy. In lung cancer, for example, the appearance of the tumor determines both which chemotherapies are safe and which chemotherapies are effective. In addition, tumor appearance also suggests which patients should be tested for mutations that can be targeted by some of the most effective and safest drugs on the market.

UNC study highlights diagnosis of lung cancer subtypes - Read More…